A New Milestone in Oncology Research Abbisko Therapeutics has recently shared encouraging news regarding their clinical development program. The company announced positive preliminary results from their Phase 2 clinical trial evaluating lavengratinib (ABSK061), a novel therapeutic candidate designed to address specific patient populations in oncology. Understanding the Clinical Breakthrough Lavengratinib (ABSK061) represents a specialized approach…